March 19 (SeeNews) - German pharmaceuticals maker Stada's Serbian unit recorded sales of 147.9 million euro ($167.9 million) last year, up from 138.2 million euro in 2017, the company said on Tuesday.
Stada's non-current assets in Serbia fell to 289.3 million euro in 2018 from 292.1 million euro in the previous year, Stada said in an annual financial report posted on its website.
In February 2018, Serbian drug maker Hemofarm, which was acquired by Stada in 2006, said it assumed from its German parent responsibility for the markets of Poland, the Czech Republic and Slovakia, becoming a hub for Central and Eastern Europe.
Stada booked a consolidated adjusted net income of 284 million euro last year, up 45%, while its sales adjusted for currency and portfolio effects increased by 5% to 2.33 billion euro, the company said.
($ = 0.8810 euro)